Back to search
Recurrent Group 3 Medulloblastoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Group 3 Medulloblastoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Group 3 Medulloblastoma trials you may qualify forThis is a pilot study in a small number of children and young adults with suspected recurrent/progressive medulloblastoma (MB) looking at the feasibility and sa…
SJELIOT is a phase 1 trial that aims to explore the combination of prexasertib with established DNA-damaging agents used in medulloblastoma to evaluate toleranc…
Approximately 90% of children with malignant brain tumors that have recurred or relapsed after receiving conventional therapy will die of disease. Despite this…